Tamoxifen for early breast cancer

  • Withdrawn
  • Review
  • Intervention


Reason for withdrawal from publication

The most up-to-date results from the EBCTCG overview are available from the Clinical Trial Service Unit and Epidemiological Studies Unit website (http://www.ctsu.ox.ac.uk/projects/ebctcg/) and reprints of the EBCTCG papers can be requested by emailing bc.overview@ctsu.ox.ac.uk

The Early Breast Cancer Trialists Collaborative Group (EBCTCG) conducts periodically updated individual patient data meta-analyses of randomised trials pertaining to the effects of local and systemic therapy on recurrence, second cancers and mortality. These systematic reviews are of the highest quality, are updated every five years and are published in prominent peer-reviewed journals. They represent the best available evidence on the effects of these treatments on relapse, second cancer and death.  

Converting each of the EBCTCG reviews into a Cochrane format as they are updated represents unnecessary duplication of effort and this Cochrane review, which was based on earlier cycles of data collection and analysis by the EBCTCG, has now been withdrawn.